Next Article in Journal
A Novel Approach for Nucleic Acid Delivery Into Cancer Cells
Previous Article in Journal
The First Evidence of Hereditary and Familial Gastric Cancer in Latvia: Implications for Prevention
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Pharmacovigilance and Principle of Nonmaleficence in Sex Reassignment

Department of Biolaw, Faculty of Law, Mykolas Romeris University, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2012, 48(11), 88; https://doi.org/10.3390/medicina48110088
Received: 25 May 2011 / Accepted: 29 November 2012 / Published: 4 December 2012
Physicians are obliged to provide treatment that is consistent with their commitment to avoid or minimize harm (nonmaleficence) and their commitment to do good (beneficence). Therefore, if patient’s desires were contradictory to the primary aim of medicine, the doctor’s calling would require him/her to thoroughly analyze the cause of the disease and provide an adequate as well as ethical treatment rather than obediently follow patient’s requests. Yet, chemical and surgical sex reassignment is one of the areas where some physicians surrender to the desire of their patients instead of finding out what their real condition is and trying to manage it in a way the essence of medicine would require. The objective of this article was to provide specific pharmacovigilance search details for the evaluation of the current situation and the scientific background of the treatment of gender dysphoria and to analyze its conformity with one of the two main ethical principles of medicine – nonmaleficence. Literature retrieval was accessed through Medline (1979–2011) using the terms “gender dysphoria,” “replacement hormonal therapy,” and “pharmacovigilance.” The article concludes that hormonal and surgical interventions have not proven to be medically justified and could be harmful, not treating the cause, but resulting in irreversible disability. Thus, these interventions contradict the principle of nonmaleficence and goals of basic therapeutics and pharmacovigilance. They are not based on clinical trials and are lacking a thorough follow-up assessment.
Keywords: gender dysphoria; replacement hormonal therapy; pharmacovigilance; ethics; sex reassignment gender dysphoria; replacement hormonal therapy; pharmacovigilance; ethics; sex reassignment
MDPI and ACS Style

Zamarytė, K.; Stakišaitis, D.; Širinskienė, A.; Narbekovas, A.; Juškevičius, J. Pharmacovigilance and Principle of Nonmaleficence in Sex Reassignment. Medicina 2012, 48, 88.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop